NCT07259278Recruiting
Intelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients
Artificial Intelligence-enhanced Stratified Management Platform Guiding Home-based Exercise Rehabilitation for Coronary Heart Disease Patients: a Randomized Control Trial
Source: ClinicalTrials.gov · Last updated 2 Dec 2025
Brief summary (registry, in English)
The goal of this clinical trial is to find out if an artificial intelligence (AI)-enabled stratified management platform can help adults with coronary heart disease (CHD) better perform exercise rehabilitation and manage their health after being discharged from the hospital. The main questions it aims to answer are: 1. Does using the AI platform lead to a greater improvement in exercise capacity (measured by peak oxygen consumption, VO2peak) after 3 months? 2. Does the platform help increase daily physical activity, improve exercise adherence and motivation, and better control modifiable cardiovascular risk factors? 3. Is guiding home-based exercise with this platform safe for low-risk CHD patients? Researchers will compare the AI Management Group (using the platform and a sports wristband) to the Routine Management Group (receiving usual care without the platform) to see if the AI group shows more significant improvements in fitness and health metrics. Participants will: 1. Be randomly assigned to either use the AI platform or receive usual post-discharge care. 2. Receive a personalized exercise prescription from a doctor before going home. 3. If in the AI group: Use the smartphone app and wearable device to track health data for comprehensive post-discharge management, and receive reminders and immediate safety alerts. 4. Attend a follow-up visit at 3 months for check-ups and tests, including an exercise test and health assessments. The study hopes to show that this intelligent management platform is an effective and safe tool to help people with CHD recover at home, stay active, and reduce future heart risks.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Diseases
- Coronary artery disease
- NCT number
- NCT07259278
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 1 Dec 2025 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Acute myocardial infarction within the past 1 month;
- Severe cognitive impairment;
- Advanced-stage malignancy;
- Severe multi-organ failure;
- Other conditions deemed unsuitable for home-based exercise rehabilitation following assessment by a specialist rehabilitation physician.
Other
- Residual stenosis of \>50% in the left main coronary artery, or \>70% stenosis in other major epicardial vessels;
- Planned coronary revascularization within the next 3 months;
- Severely impaired exercise capacity.
- Life expectancy less than 3 months;
- Refusal to provide written informed consent.
Who the study is looking for
- CHD patients aged over 18 years;
- Stratified as low-risk for cardiovascular events during exercise and classified as low-risk according to the GRACE risk score.
- Ability of the patient or close relatives to use smartphones and applications;
- Willingness to participate and sign the informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Diseases Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.